BAXTER INTERNATIONAL INC
BAXAPI behind this page
BAX Q1 2026 request
Playground key active
/api/financials?ticker=BAX&year=2026&quarter=1
Pick an endpoint and run the request.Income Statement
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Revenue | 2,701 | 2,625 | +2.9% |
Show Product Lines breakouts |
|||
| Advanced Surgery · Medical Products & Therapies | 165 | 145 | +13.8% |
| Advanced Surgery · Medical Products & Therapies | 139 | 123 | +13.0% |
| Advanced Surgery · Medical Products & Therapies | 304 | 268 | +13.4% |
| Care & Connectivity Solutions · Healthcare Systems & Technologies | 315 | 316 | -0.3% |
| Care & Connectivity Solutions · Healthcare Systems & Technologies | 120 | 111 | +8.1% |
| Care & Connectivity Solutions · Healthcare Systems & Technologies | 435 | 427 | +1.9% |
| Drug Compounding · Pharmaceuticals | 320 | 246 | +30.1% |
| Drug Compounding · Pharmaceuticals | 320 | 246 | +30.1% |
| Front Line Care · Healthcare Systems & Technologies | 198 | 202 | -2.0% |
| Front Line Care · Healthcare Systems & Technologies | 72 | 75 | -4.0% |
| Front Line Care · Healthcare Systems & Technologies | 270 | 277 | -2.5% |
| Infusion Therapies & Technologies · Medical Products & Therapies | 526 | 584 | -9.9% |
| Infusion Therapies & Technologies · Medical Products & Therapies | 455 | 410 | +11.0% |
| Infusion Therapies & Technologies · Medical Products & Therapies | 981 | 994 | -1.3% |
| Injectables & Anesthesia · Pharmaceuticals | 180 | 195 | -7.7% |
| Injectables & Anesthesia · Pharmaceuticals | 121 | 140 | -13.6% |
| Injectables & Anesthesia · Pharmaceuticals | 301 | 335 | -10.1% |
Show Business Segments breakouts |
|||
| Healthcare Systems & Technologies · Non Us | 192 | 186 | +3.2% |
| Healthcare Systems & Technologies · Operating Segments | 705 | 704 | +0.1% |
| Healthcare Systems & Technologies · US | 513 | 518 | -1.0% |
| Medical Products & Therapies · Non Us | 594 | 533 | +11.4% |
| Medical Products & Therapies · Operating Segments | 1,285 | 1,262 | +1.8% |
| Medical Products & Therapies · US | 691 | 729 | -5.2% |
| Pharmaceuticals · Non Us | 441 | 386 | +14.2% |
| Pharmaceuticals · Operating Segments | 621 | 581 | +6.9% |
| Pharmaceuticals · US | 180 | 195 | -7.7% |
Show Geography breakouts |
|||
| Non Us | 1,266 | 1,135 | +11.5% |
| Non Us · Corporate Non Segment | 39 | 30 | +30.0% |
| US | 1,435 | 1,490 | -3.7% |
| US · Corporate Non Segment | 51 | 48 | +6.2% |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | 90 | 78 | +15.4% |
| Cost of Revenue | 1,810 | 1,764 | +2.6% |
Show Business Segments breakouts |
|||
| Healthcare Systems & Technologies · Operating Segments | 390 | 356 | +9.6% |
| Medical Products & Therapies · Operating Segments | 781 | 694 | +12.5% |
| Pharmaceuticals · Operating Segments | 458 | 396 | +15.7% |
Show Equity Components breakouts |
|||
| Accumulated Gain Loss Net Cash Flow Hedge Parent · Interest Rate Contract | 1 | -4 | +125.0% |
| Gross Profit | 891 | 861 | +3.5% |
| Selling, General & Administrative | 728 | 703 | +3.6% |
Show Business Segments breakouts |
|||
| Healthcare Systems & Technologies · Operating Segments | 209 | 217 | -3.7% |
| Medical Products & Therapies · Operating Segments | 290 | 286 | +1.4% |
| Pharmaceuticals · Operating Segments | 102 | 103 | -1.0% |
| Research & Development | 139 | 140 | -0.7% |
Show Business Segments breakouts |
|||
| Healthcare Systems & Technologies · Operating Segments | 49 | 45 | +8.9% |
| Medical Products & Therapies · Operating Segments | 54 | 59 | -8.5% |
| Pharmaceuticals · Operating Segments | 22 | 26 | -15.4% |
| Other Operating Income Expense Net | -42 | -40 | -5.0% |
| Operating Income | 66 | 58 | +13.8% |
Show Business Segments breakouts |
|||
| Healthcare Systems & Technologies · Operating Segments | 66 | 93 | -29.0% |
| Medical Products & Therapies · Operating Segments | 186 | 244 | -23.8% |
| Pharmaceuticals · Operating Segments | 46 | 63 | -27.0% |
| Reportable Segment · Operating Segments | 298 | 400 | -25.5% |
| Interest Income Expense Nonoperating Net | 66 | 64 | +3.1% |
| Other Non-Operating Income (Expense) | 6 | -3 | +300.0% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment · Reclassification Out Of Accumulated Other Comprehensive Income | 3 | -3 | +200.0% |
| Income Before Taxes | -6 | -3 | -100.0% |
| Income Tax Expense (Benefit) | 11 | -67 | +116.4% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment · Reclassification Out Of Accumulated Other Comprehensive Income | -1 | 1 | -200.0% |
| Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest | -17 | 64 | -126.6% |
| Income Loss From Discontinued Operations Net Of Tax | 2 | 62 | -96.8% |
| Net Income | -15 | 126 | -111.9% |
Show Equity Components breakouts |
|||
| Parent | -15 | 126 | -111.9% |
| Retained Earnings | -15 | 126 | -111.9% |
| Net Income | -15 | 126 | -111.9% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment · Reclassification Out Of Accumulated Other Comprehensive Income | -2 | 13 | -115.4% |
| Accumulated Gain Loss Net Cash Flow Hedge Parent · Reclassification Out Of Accumulated Other Comprehensive Income | -1 | 2 | -150.0% |
Show Reclassification Out Of Accumulated Other Comprehensive Income breakouts |
|||
| Reclassification Out Of Accumulated Other Comprehensive Income | -3 | -111 | +97.3% |
| Income Loss From Continuing Operations Per Basic Share | -0.03 | 0.13 | -123.1% |
| Income Loss From Continuing Operations Per Diluted Share | -0.03 | 0.13 | -123.1% |
| EPS (Basic) | -0.03 | 0.25 | -112.0% |
| EPS (Diluted) | -0.03 | 0.25 | -112.0% |
| Wtd Avg Shares (Basic) | 515 | 512 | +0.6% |
| Wtd Avg Shares (Diluted) | 515 | 514 | +0.2% |
| Interest Expense | -12 | -17 | +29.4% |
| Comprehensive Income | -63 | 194 | -132.5% |
| Operating Lease Lease Income | 90 | 91 | -1.1% |
| Other Expenses (Q) | — | — | — |
Show Business Segments breakouts |
|||
| Healthcare Systems & Technologies · Operating Segments | -9 | -7 | -28.6% |
| Medical Products & Therapies · Operating Segments | -26 | -21 | -23.8% |
| Pharmaceuticals · Operating Segments | -7 | -7 | 0.0% |
Balance Sheet
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 2,017 | 2,294 | -12.1% |
| Accounts Receivable | 1,698 | 1,646 | +3.2% |
| Inventory | 2,316 | 2,170 | +6.7% |
| Prepaid Expenses & Other Current Assets | 816 | 925 | -11.8% |
| Total Current Assets | 6,847 | 7,035 | -2.7% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 2,913 | 2,717 | +7.2% |
| Goodwill | 4,899 | 5,338 | -8.2% |
Show Business Segments breakouts |
|||
| Healthcare Systems & Technologies | 3,082 | 3,558 | -13.4% |
| Medical Products & Therapies | 1,248 | 1,223 | +2.0% |
| Pharmaceuticals | 569 | 557 | +2.2% |
| Operating Lease Right-of-Use Assets | 277 | 301 | -8.0% |
| Other Non-Current Assets | 692 | 832 | -16.8% |
| Total Assets | 19,846 | 21,304 | -6.8% |
| Intangible Assets (Q) | — | — | — |
Show Finite Lived Intangible Assets By Major Class breakouts |
|||
| Customer Relationships | 2,244 | 2,457 | -8.7% |
| Developed technology, including patents | 696 | 984 | -29.3% |
| Other Intangible Assets | 18 | 19 | -5.3% |
| Trade Names | 763 | 834 | -8.5% |
| Other Assets | |||
| Intangible Assets Net Excluding Goodwill | 4,218 | 5,081 | -17.0% |
| Current Liabilities | |||
| Long Term Debt And Capital Lease Obligations Current | 842 | 651 | +29.3% |
| Accounts Payable | 1,086 | 963 | +12.8% |
| Accrued Liabilities | 1,765 | 1,856 | -4.9% |
| Total Current Liabilities | 3,693 | 3,481 | +6.1% |
| Non-Current Liabilities | |||
| Operating Lease Liabilities | 224 | 235 | -4.7% |
| Other Non-Current Liabilities | 1,292 | 1,122 | +15.2% |
| Total Liabilities | 13,830 | 14,250 | -2.9% |
| Other Liabilities | |||
| Long Term Debt And Lease Obligation Excluding Current Maturities | 8,621 | 9,412 | -8.4% |
| Stockholders' Equity | |||
| Common Stock | 683 | 683 | 0.0% |
| Treasury Stock Common Value | -10,737 | -10,937 | +1.8% |
| Additional Paid In Capital Common Stock | 6,214 | 6,309 | -1.5% |
| Retained Earnings | 13,685 | 14,968 | -8.6% |
| Accumulated Other Comprehensive Income | -3,802 | -3,942 | +3.6% |
| Total Stockholders' Equity | 6,043 | 7,081 | -14.7% |
| Minority Interest | -27 | -27 | 0.0% |
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 6,016 | 7,054 | -14.7% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment | -511 | -474 | -7.8% |
| Accumulated Gain Loss Net Cash Flow Hedge Parent | -109 | -110 | +0.9% |
| Accumulated Net Unrealized Investment Gain Loss | 3 | 3 | 0.0% |
| Accumulated Other Comprehensive Income | -3,802 | -3,942 | +3.6% |
| Accumulated Translation Adjustment | -3,185 | -3,361 | +5.2% |
| Additional Paid In Capital | 6,214 | 6,309 | -1.5% |
| Common Stock | 683 | 683 | 0.0% |
| Noncontrolling Interest | -27 | -27 | 0.0% |
| Parent | 6,043 | 7,081 | -14.7% |
| Retained Earnings | 13,685 | 14,968 | -8.6% |
| Treasury Stock Common | -10,737 | -10,937 | +1.8% |
| Total Liabilities & Equity | 19,846 | 21,304 | -6.8% |
Cash Flow Statement
| Metric | YTD Q1 2026 | YTD Q1 2025 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation & Amortization | 237 | 247 | -4.0% |
| Deferred Income Taxes And Tax Credits | 29 | -142 | +120.4% |
| Stock-Based Compensation | 10 | 10 | 0.0% |
| Pension And Other Postretirement Benefits Expense Reversal Of Expense Noncash | -4 | -8 | +50.0% |
| Other Non-Cash Items | 13 | 6 | +116.7% |
| Change in Accounts Receivable | 152 | 26 | +484.6% |
| Change in Inventory | -95 | -122 | +22.1% |
| Change in Prepaid & Other Assets | 2 | -24 | +108.3% |
| Change in Accounts Payable | 102 | 16 | +537.5% |
| Increase Decrease In Accrued Expenses And Other Current Liabilities | -203 | -143 | -42.0% |
| Other Operating Activities Cash Flow Statement | -13 | -51 | +74.5% |
| Net Cash Provided By Used In Operating Activities Continuing Operations | 213 | -99 | +315.2% |
| Net Cash from Operations | 213 | -193 | +210.4% |
| Investing Activities | |||
| Payments To Acquire Other Productive Assets | -137 | -122 | -12.3% |
| Other Investing Activities | 4 | -2 | +300.0% |
| Net Cash Provided By Used In Investing Activities Continuing Operations | -133 | -124 | -7.3% |
| Net Cash from Investing | -133 | 3,265 | -104.1% |
| Financing Activities | |||
| Payments Of Dividends Common Stock | -5 | -87 | +94.3% |
| Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options | 8 | 10 | -20.0% |
| Proceeds From Payments For Other Financing Activities | -14 | -24 | +41.7% |
| Net Cash from Financing | -11 | -3,226 | +99.7% |
| Supplemental | |||
| Unpaid Capital Expenditures (Q) | — | — | — |
Show Property Plant And Equipment By Type breakouts |
|||
| Property Plant And Equipment | 54 | 39 | +38.5% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | -18 | 36 | -150.0% |
| Net Change in Cash | 51 | -118 | +143.2% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | 2,019 | 2,296 | -12.1% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 2,019 | 2,296 | -12.1% |
Values in millions USD. Source: SEC EDGAR 10-Q filing.